Sponsors (19)
The bill strengthens and extends orphan-drug protections to preserve incentives and revenue for rare-disease drug development, but does so at the cost of delaying drug price negotiations — reducing near-term savings and keeping prices higher longer for Medicare/Medicaid beneficiaries, patients, and health systems.
Manufacturers and rare-disease drug developers: the bill extends or preserves orphan-exclusivity protections and excludes more orphan-protected time from price negotiations, allowing longer market exclusivity and higher revenue potential that helps sustain investment in these products.
Patients with rare diseases: strengthened orphan protections may preserve or increase incentives for R&D into rare conditions, improving the likelihood that new therapies for those conditions will be developed and become available.
Medicare and Medicaid beneficiaries and taxpayers: delaying affected drugs' inclusion in the Drug Price Negotiation Program reduces near-term federal savings and increases program costs.
Patients who rely on negotiated price reductions (including many Medicare beneficiaries): may face higher drug prices and out-of-pocket costs for longer because drugs that had orphan status can avoid earlier negotiation.
Hospitals, insurers, and health systems: extended exclusion of drugs from negotiated pricing can increase spending for providers and payers, which may translate into higher premiums or costs for health systems.
Based on analysis of 2 sections of legislative text.
Stops counting time a product held orphan-drug status toward the Drug Price Negotiation Program eligibility clock and broadens the orphan definition to cover multiple rare conditions.
Official title: To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
Introduced February 4, 2025 by John Joyce · Last progress February 4, 2025
Changes the Drug Price Negotiation Program so periods when a drug had orphan-drug status do not count toward the program’s elapsed-time calculation for negotiation eligibility, and expands the orphan definition to cover products approved for one or more rare diseases or conditions. In short, prior orphan periods would be excluded from the clock that determines when a drug becomes eligible for price negotiation, and the orphan exclusion would explicitly apply when a product treats multiple rare conditions.